# Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

> **NCT06006013** · PHASE2 · RECRUITING · sponsor: **Emory University** · enrollment: 21 (estimated)

## Conditions studied

- Locally Advanced Adrenal Cortex Carcinoma
- Adrenal Cortical Carcinoma
- Stage III Adrenal Cortex Carcinoma
- Stage IV Adrenal Cortex Carcinoma AJCC v8
- Unresectable Adrenal Cortex Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cabozantinib S-malate
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT06006013
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2027-12-16
- **Final completion:** 2028-12-16
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06006013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06006013, "Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06006013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*